Skip to content

April 27, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
Novartis secures pair of regulatory wins for skin disease and malaria treatments

Regulatory

Novartis secures pair of regulatory wins for skin disease and malaria treatments

Pharmaceutical Technology

Novartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

Pharmaceutical Technology

Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.

Read full story

Post navigation

Previous: New NIHR-funded TRC for Parkinson’s disease

Next: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

Related Stories

Regulatory

UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention

pharminent April 27, 2026

Regulatory

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

pharminent April 24, 2026

Regulatory

FDA clears first genetic hearing loss gene therapy

pharminent April 24, 2026

You May Have Missed

Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

pharminent April 27, 2026

Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.